Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509430 | 0.90 | PTGER1 (0.36) | PTGER1CCR2CETP | |
| SCHEMBL7982392 | 0.88 | TRPV1 (0.35) | PTGER1TRPV1CETP | |
| SCHEMBL7515851 | 0.87 | PTGER1 (0.34) | PTGER1CCR2CETP | |
| SCHEMBL7982400 | 0.87 | F2 (0.39) | PTGER1TRPV1CETP | |
| SCHEMBL7511101 | 0.86 | PTGER1 (0.36) | PTGER1CCR2CETP | |
| SCHEMBL8047834 | 0.85 | PTGER1 (0.38) | PTGER1CCR2 | |
| SCHEMBL7572801 | 0.85 | F2 (0.38) | PTGER1CETP | |
| SCHEMBL7516138 | 0.83 | PTGER1 (0.36) | PTGER1CCR2CETP | |
| SCHEMBL7511096 | 0.83 | GAA (0.35) | PTGER1CCR2CETP | |
| SCHEMBL7519501 | 0.83 | PTGER1 (0.37) | PTGER1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | claimed |
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |